Cancer Drug Websites May Overstate Benefits, Minimize Risks

Websites from pharmaceutical companies that promote cancer drugs are much more likely to provide data that backs up claims about the medications’ benefit while providing scant details about the risks associated with them.

The FDA’s Office of Prescription Drug Promotion, along with RTI International, examined 65 websites –- 57 from brand oncology drugs, and 8 from medications that treat related side effects. While almost all of the sites provided quantitative data on both the benefits and the risks, the amount of data for each varied greatly.

For direct-to-consumer websites, 38.5% contained quantitative data on all of the benefits, but only 3.1% provided such data on all the drugs’ risks, the researchers reported in the Journal of Cancer Education. For websites geared towards healthcare providers, the figures were, respectively, 86.1% and 6.2%.

The researchers noted that that websites were also much more likely than print ads to provide numbers on benefits versus risks, a move that could potentially overstate the benefits of a drug to consumers.

“Research has shown that using quantitative information to communicate treatment benefits and risks can increase patients’ and physicians’ understanding and can aid in treatment decision-making,” the authors wrote.


Did you find this article helpful?


Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

More Drugs Linked to Heart Failure

More Drugs Linked to Heart Failure

Pulmonary arterial hypertension is a disease of the lungs that can cause heart failure and death, and it’s being linked to an increasing number of common and oft-prescribed drugs. The journal Prescrire, reports that, as of 2020, amphetamines, immunosuppressants, certain cancer medications, and a handful of other select medications have been…

Significant Side Effects Seen in Early Trial of COVID-19 Vaccine

Significant Side Effects Seen in Early Trial of COVID-19 Vaccine

There’s a COVID-19 vaccine on the way — or so the Wednesday headlines, which heralded positive results from Pfizer and BioNTech’s early-stage trial of a vaccine for COVID-19, would lead you to believe. A closer look at the data, and the adverse effects, however, reveals that it’s probably too early…

  • Advertisement